$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016763 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$42.00K	$49.00K	$33.00K
YoY Change	40.0%	48.48%	17.86%
Cost Of Revenue	$0.00	$0.00	$77.00K
YoY Change	-100.0%	-100.0%	-67.51%
Gross Profit	$42.00K	$49.00K	-$44.00K
YoY Change	-207.69%	-211.36%	-78.95%
Gross Profit Margin	100.0%	100.0%	-133.33%
Selling, General & Admin	$2.550M	$2.292M	$2.072M
YoY Change	16.92%	10.62%	-1.89%
% of Gross Profit	6071.43%	4677.55%
Research & Development	$2.953M	$2.052M	$1.036M
YoY Change	19.31%	98.07%	-27.25%
% of Gross Profit	7030.95%	4187.76%
Depreciation & Amortization	$80.00K	$11.00K	$29.00K
YoY Change	175.86%	-62.07%	-87.22%
% of Gross Profit	190.48%	22.45%
Operating Expenses	$2.953M	$2.052M	$3.108M
YoY Change	19.31%	-33.98%	-12.1%
Operating Profit	-$5.461M	-$4.295M	-$3.152M
YoY Change	16.32%	36.26%	-15.83%
Interest Expense		$402.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$318.0K	$199.0K	$31.00K
YoY Change	10500.0%	541.94%	-183.78%
Pretax Income	-$4.909M	-$3.661M	-$3.820M
YoY Change	1.2%	-4.16%	6.73%
Income Tax
% Of Pretax Income
Net Earnings	-$4.909M	-$3.661M	-$3.820M
YoY Change	1.2%	-4.16%	6.73%
Net Earnings / Revenue	-11688.1%	-7471.43%	-11575.76%
Basic Earnings Per Share	-$0.10	-$0.08	-$0.08
Diluted Earnings Per Share	-$0.10	-$0.08	-$79.59K
COMMON SHARES
Basic Shares Outstanding	48.41M shares	48.41M shares
Diluted Shares Outstanding	48.41M shares	48.40M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.40M	$30.85M	$44.54M
YoY Change	-32.02%	-30.74%	-10.8%
Cash & Equivalents	$21.04M	$23.40M	$28.99M
Short-Term Investments	$7.360M	$7.454M	$15.55M
Other Short-Term Assets	$438.0K	$548.0K	$4.196M
YoY Change	-89.75%	-86.94%	2555.7%
Inventory
Prepaid Expenses
Receivables	$33.00K	$1.763M	$1.641M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.87M	$33.16M	$50.38M
YoY Change	-37.3%	-34.18%	-1.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$145.0K	$155.0K	$281.0K
YoY Change	14.17%	-44.84%	-95.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.784M	$1.457M	$1.506M
YoY Change	-1.49%	-3.25%	62.11%
Total Long-Term Assets	$4.748M	$4.302M	$3.775M
YoY Change	-1.88%	13.96%	-83.49%
TOTAL ASSETS
Total Short-Term Assets	$28.87M	$33.16M	$50.38M
Total Long-Term Assets	$4.748M	$4.302M	$3.775M
Total Assets	$33.62M	$37.46M	$54.16M
YoY Change	-33.93%	-30.82%	-26.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.151M	$963.0K	$378.0K
YoY Change	202.11%	154.76%	100.0%
Accrued Expenses	$528.0K	$696.0K	$388.0K
YoY Change	5.18%	79.38%	-29.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.885M	$1.837M	$766.0K
YoY Change	110.89%	139.82%	-21.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$597.0K	$636.0K	$88.00K
YoY Change	-18.89%	622.73%	-73.81%
Total Long-Term Liabilities	$597.0K	$636.0K	$88.00K
YoY Change	-18.89%	622.73%	-95.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.885M	$1.837M	$766.0K
Total Long-Term Liabilities	$597.0K	$636.0K	$88.00K
Total Liabilities	$3.482M	$2.473M	$854.0K
YoY Change	65.49%	189.58%	-72.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$389.1M	-$384.2M
YoY Change	5.23%
Common Stock	$48.00K	$48.00K
YoY Change	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.14M	$34.99M	$53.30M
YoY Change
Total Liabilities & Shareholders Equity	$33.62M	$37.46M	$54.16M
YoY Change	-33.93%	-30.82%	-26.91%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.909M	-$3.661M	-$3.820M
YoY Change	1.2%	-4.16%	6.73%
Depreciation, Depletion And Amortization	$80.00K	$11.00K	$29.00K
YoY Change	175.86%	-62.07%	-87.22%
Cash From Operating Activities	-$2.158M	-$3.680M	-$2.758M
YoY Change	-6.7%	33.43%	-9.43%
INVESTING ACTIVITIES
Capital Expenditures	$203.0K		-$33.00K
YoY Change	-572.09%		-90.96%
Acquisitions
YoY Change
Other Investing Activities	-$1.000K	-$78.00K	-$313.0K
YoY Change	-100.01%	-75.08%	-135.25%
Cash From Investing Activities	-$204.0K	-$78.00K	-$346.0K
YoY Change	-102.64%	-77.46%	-166.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.000K	$100.0K
YoY Change	-90.91%
NET CHANGE
Cash From Operating Activities	-2.158M	-$3.680M	-2.758M
Cash From Investing Activities	-204.0K	-$78.00K	-346.0K
Cash From Financing Activities	5.000K	$100.0K
Net Change In Cash	-2.357M	-$3.658M	$0.00
YoY Change	-143.14%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.158M	-$3.680M	-$2.758M
Capital Expenditures	$203.0K		-$33.00K
Free Cash Flow	-$2.361M		-$2.725M
YoY Change	4.01%		1.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment		usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred		usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Entity File Number EntityFileNumber	001-27072
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
CY2023Q1	dei	City Area Code CityAreaCode	(352)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	448-7797
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	AIM
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48408295	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23395000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27053000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7454000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1763000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1676000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	548000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	455000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	33160000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36321000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	792000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1898000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1941000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1457000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1202000	usd
CY2023Q1	us-gaap	Assets Assets	37462000	usd
CY2022Q4	us-gaap	Assets Assets	40488000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	963000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	377000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	696000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1837000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1361000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	636000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	659000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	692000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	696000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48407326	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48407326	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418456000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418270000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384207000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380546000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37462000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40488000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33000	usd
CY2023Q1	us-gaap	Revenues Revenues	49000	usd
CY2022Q1	us-gaap	Revenues Revenues	33000	usd
CY2022Q1	us-gaap	Manufacturing Costs ManufacturingCosts	77000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2052000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1036000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2292000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2072000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	4344000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	3185000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4295000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3152000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	203000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-934000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	199000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-31000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	usd
CY2023Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-255000	usd
CY2022Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-190000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3661000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3820000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48399950	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47994672	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3661000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	242000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3820000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53301000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53301000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3661000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3820000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	10000	usd
CY2022Q1	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment	-31000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19000	usd
CY2023Q1	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	37000	usd
CY2022Q1	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	5000	usd
CY2022Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-19000	usd
CY2023Q1	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	255000	usd
CY2022Q1	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	190000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	82000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	242000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	203000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-915000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	180000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-23000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	586000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	180000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-110000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-110000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3680000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2758000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	598000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	407000	usd
CY2023Q1	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	-7000	usd
CY2022Q1	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	33000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	712000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	720000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	29000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-346000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	100000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3658000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3104000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23395000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28989000	usd
CY2023Q1	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	4000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	150000	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	134000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	729000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7454000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	7454000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7454000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	290000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-87000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	203000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	7137000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1679000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-751000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-928000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	492000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	378000	usd
CY2023Q1	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	209000	usd
CY2022Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	110000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	92000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	696000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	10000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1800000000	usd
CY2022Q4	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3700000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1974000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	375000	usd
CY2022	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	190	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	218000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2023Q1	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	7	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1898000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	128000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	167000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	162000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	160000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	149000	usd
CY2023Q1	AIM	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1132000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1898000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48407326	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2023Q1	AIM	Percentage Of Probability PercentageOfProbability	0.050	pure
CY2023Q1	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure
CY2023Q1	us-gaap	Derivative Assets DerivativeAssets	7454000	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	7137000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P25M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P28M
CY2023Q1	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2022	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	203000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	242000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	216000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	200000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	133000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	178000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	815000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	792000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	815000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
CY2023Q1	us-gaap	Short Term Lease Payments ShortTermLeasePayments	87000	usd
CY2022Q1	us-gaap	Short Term Lease Payments ShortTermLeasePayments	17000	usd
CY2023Q2	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.030	pure
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	969	shares
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	485	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	3	pure
CY2023Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	15	usd

Files In Submission

Name	View Source	Status
0001493152-23-016763-index-headers.html	Edgar Link	pending
0001493152-23-016763-index.html	Edgar Link	pending
0001493152-23-016763.txt	Edgar Link	pending
0001493152-23-016763-xbrl.zip	Edgar Link	pending
aim-20230331.xsd	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
aim-20230331_cal.xml	Edgar Link	unprocessable
aim-20230331_def.xml	Edgar Link	unprocessable
aim-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aim-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2023 Q2 Form 10-Q Financial Statement

#000149315223016763 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2023 Q2 Form 10-Q Financial Statement

#000149315223016763 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim